Lyngby, Denmark

Henrik Sune Andersen

USPTO Granted Patents = 63 

 

Average Co-Inventor Count = 4.9

ph-index = 15

Forward Citations = 822(Granted Patents)

Forward Citations (Not Self Cited) = 777(Oct 12, 2025)


Inventors with similar research interests:


Location History:

  • K.phi.benhaven .phi., DK (1997)
  • K.o slashed.benhaven, DK (1997 - 1998)
  • Tjele, DK (1999)
  • Kobenhavn, DK (1999)
  • V.ae butted.rl.o slashed.se, DK (1999)
  • K.o slashed.benjavn, DK (1999)
  • Copenhagen, DK (1993 - 2000)
  • K.o slashed.benhavn, DK (1997 - 2000)
  • K.o slashed.benhaven .O slashed., DK (1997 - 2000)
  • K.o slashed.benhavn .O slashed., DK (1998 - 2000)
  • Kobenhavn O, DK (2000)
  • København, DK (2001 - 2003)
  • Vaerloese, DK (2004)
  • Kgs. Lyngby, DK (2010)
  • Holte Ihsa, DK (2012)
  • Lyngby, DK (2001 - 2014)
  • Holte, DK (2013 - 2017)

Company Filing History:


Years Active: 1993-2017

Loading Chart...
Loading Chart...
63 patents (USPTO):

Title: Innovations of Henrik Sune Andersen

Introduction

Henrik Sune Andersen is a renowned inventor based in Lyngby, Denmark, known for his significant contributions to the field of inflammatory disease treatment. With an impressive portfolio of 63 patents, his work has substantially impacted medical research and therapeutic advancements.

Latest Patents

Among his latest innovations are the antagonistic DR3 ligands, which are pivotal in treating inflammatory diseases. The current disclosures highlight the utility of these ligands as therapeutic agents, providing fresh avenues for the management of various inflammatory conditions.

Career Highlights

Henrik has built an illustrious career with notable organizations in the pharmaceutical industry, including Novo Nordisk A/S and High Point Pharmaceuticals, LLC. His tenure at these companies has allowed him to spearhead research and development initiatives that translate into patented innovations.

Collaborations

Throughout his career, Henrik has collaborated with esteemed colleagues such as Knud Erik Andersen and Uffe Bang Olsen. These partnerships have fostered a rich environment of knowledge exchange and innovation, resulting in groundbreaking discoveries that advance therapeutic strategies.

Conclusion

In summary, Henrik Sune Andersen exemplifies the essence of innovation in the pharmaceutical field. Through his extensive patent portfolio and collaborative efforts, he continues to push the boundaries of treatment for inflammatory diseases, making a lasting impact on both the scientific community and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…